A recent review outlines the burden, risk factors, and management strategies for reducing recurrence of overt hepatic encephalopathy (OHE), a neurologic complication of advanced liver disease. The review, published on Jul. 31, highlights that OHE impairs functioning, quality of life, and increases both hospitalization rates and mortality.
The review identifies key precipitants of OHE including medications such as sedatives and opioids, constipation, dehydration, uncontrolled diabetes, electrolyte imbalances, gastrointestinal bleeding, infection, and sarcopenia. Management approaches discussed include patient education to improve adherence to therapy—only 35% are adherent to lactulose—and nutritional support with recommended daily intake levels. Pharmacologic interventions such as lactulose for secondary prophylaxis are recommended by guidelines; rifaximin is added if further episodes occur. Other options like polyethylene glycol (PEG) and L-ornithine L-aspartate (LOLA) may be considered in certain patients.
Hepatic encephalopathy affects approximately 20% of U.S. adults with cirrhosis—a projected 697,000 people by 2030—and is classified based on underlying disease type or severity using West Haven criteria. OHE can manifest as lethargy or coma and may follow episodic or persistent courses. Hospitalization rates remain high: nearly 44% are rehospitalized within one year; HE is the leading cause of ninety-day readmissions at about forty-one percent. Average costs per episode exceed $77,000 with total annual inpatient charges over $11 billion.
Pathophysiology involves gut dysbiosis leading to hyperammonaemia and systemic inflammation that damages brain cells through increased permeability in the blood-brain barrier. Sarcopenia contributes by reducing muscle clearance of ammonia while releasing amino acids that generate more ammonia.
The review also emphasizes correcting precipitating factors through educational interventions—one fifteen-minute session reduced hospitalizations significantly—as well as ensuring adequate nutrition without protein restriction. Nonadherence remains a significant challenge due to medication taste or side effects.
Future directions include development of predictive models for OHE risk assessment such as AMMON-OHE algorithms and further large-scale clinical trials internationally.
